If you have Behçet’s, you could be eligible to take part in this clinical trial.
Secukinumab in Behçet’s trial aim
This study is looking at a potential new treatment, secukinumab, for patients diagnosed with non-ocular Behçet’s. This is a randomised, placebo-controlled trial of either the drug (secukinumab) or placebo and aims to evaluate how safe and how effective secukinumab might be for participants with Behçet’s.
Taking part
If you have been diagnosed with Behçet’s and have previously not responded to first-line therapy with topical steroid (mouth wash or skin cream), colchicine or azathioprine, you could be eligible to take part in the trial.
Patients are only randomised to active drug or placebo for the first part of the trial. Thereafter, all participants move on to receiving the active drug for the vast majority of the trial’s duration.
Why is it important?
This could help to make a difference to your quality of life, and in the process assist others in the future.
What should I do next?
If you would like more information about this study, contact a member of your usual Behçet’s care team or the contacts below. They will be able to discuss the study further with you, answer any questions you might have and let you know whether you are eligible to take part. However, please note that the Birmingham Centre has now closed for this trial, and only the Liverpool and London Centres can directly recruit patients
Contacts
Helen Frankland /Ayren Mediana
Aintree, Clinical Sciences Centre, Aintree University Hospital NHS FT, Lower Lane, Liverpool L9 7AL; Tel: 0151 529 5894; Email: helen. frankland@liverpoolft.nhs.uk / ayren.mediana@liverpoolft.nhs.uk
Nardos Wakjira/Dina Paolini
Behçet’s Syndrome Centre of Excellence (London), DentalHospital, The Royal London Hospital, Turner Street, Whitechapel, London E1 1BB; Tel: 0203416 5000, ext: 46089; Email: Nardos.Wakjira@nhs.net/ d.paolini@nhs.net